Depatuxizumab mafodotin clinical trials
Also written ABT-414.
How each study uses depatuxizumab mafodotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 4 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses depatuxizumab mafodotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) AmplificationCompletedPhase 3AbbVieNCT02573324Written as Depatuxizumab mafodotinHow we know
- UNITE Study: Understanding New Interventions With GBM ThErapyTerminatedPhase 3AbbVieNCT03419403Written as Depatuxizumab mafodotinHow we know
- Study Evaluating ABT-414 in Japanese Subjects With Malignant GliomaCompletedPhase 1/2AbbVieNCT02590263Written as ABT-414How we know
- Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade GliomasCompletedPhase 2AbbVieNCT02343406Written as Depatuxizumab mafodotinHow we know
- A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorTerminatedPhase 1AbbVieNCT02365662Written as ABBV-221How we know
- Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma MultiformeCompletedPhase 1AbbVieNCT01800695Written as ABT-414How we know
- A Study of ABT-414 in Subjects With Solid TumorsCompletedPhase 1AbbVie (prior sponsor, Abbott)NCT01741727Written as ABT-414How we know
Codes
What other systems call depatuxizumab mafodotin · ClinicalTrials.gg INT001111
- MeSH (NLM) C000631685depatuxizumab mafodotinOne source NLM
- UNII (FDA) F3R7A4P04NDEPATUXIZUMAB MAFODOTINConfirmed FDA, NLM, Wikidata
- Wikidata Q28209069depatuxizumab mafodotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C105612Depatuxizumab MafodotinOne source FDA
- DrugBank DB11731One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631685 | depatuxizumab mafodotin | One source NLM |
| UNII (FDA) | F3R7A4P04N | DEPATUXIZUMAB MAFODOTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q28209069 | depatuxizumab mafodotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C105612 | Depatuxizumab Mafodotin | One source FDA |
| DrugBank | DB11731 | — | One source Wikidata |
Also registered as losatuxizumab vedotin (UNII 17C83BVV62).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.